Beone Medicines Ltd.(688235)

268.60-3.40-1.25%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

- Health Canada Approves Tevimbra® (Tislelizumab for Injection) in Combination With Gemcitabine and Cisplatin for the First-Line Treatment of Adult Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
  THOMSON REUTERS · 2025-12-23
  Health Canada Approves Tevimbra® (Tislelizumab for Injection) in Combination With Gemcitabine and Cisplatin for the First-Line Treatment of Adult Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
- BeOne Medicines to Present at J.P. Morgan Healthcare Conference
  Reuters · 2025-12-23
  BeOne Medicines to Present at J.P. Morgan Healthcare Conference
- BeOne Medicines Secures New Financing Facility with HSBC-Led Lenders
  Reuters · 2025-12-19
  BeOne Medicines Secures New Financing Facility with HSBC-Led Lenders
- BeOne Medicines AG Awards Dr. Lai Wang $10 Million Equity Grant and $750,000 Salary as President of R&D
  Reuters · 2025-12-18
  BeOne Medicines AG Awards Dr. Lai Wang $10 Million Equity Grant and $750,000 Salary as President of R&D
- FDA Grants Fast Track Designation to BeOne Medicines' BGB-B2033 for Liver Cancer
  Reuters · 2025-12-18
  FDA Grants Fast Track Designation to BeOne Medicines' BGB-B2033 for Liver Cancer
- Beone Medicines Granted U.S. FDA Fast Track Designation for Bgb-B2033 as Treatment for Hepatocellular Carcinoma
  THOMSON REUTERS · 2025-12-18
  Beone Medicines Granted U.S. FDA Fast Track Designation for Bgb-B2033 as Treatment for Hepatocellular Carcinoma
- Afternoon Plunge! HUABAO HANG SENG HONG KONG STOCK CONNECT INNOVATIVE DRUG SELECTION ETF (520880) Drops 2.77% to Hit New Low, Led by Heavyweights AKESO and BEIGENE
  Deep News · 2025-12-15
  Afternoon Plunge! HUABAO HANG SENG HONG KONG STOCK CONNECT INNOVATIVE DRUG SELECTION ETF (520880) Drops 2.77% to Hit New Low, Led by Heavyweights AKESO and BEIGENE
- BeOne Medicines Reports 74% Six-Year Progression-Free Survival with BRUKINSA in Treatment-Naïve CLL
  Reuters · 2025-12-08
  BeOne Medicines Reports 74% Six-Year Progression-Free Survival with BRUKINSA in Treatment-Naïve CLL
- BeOne Medicines AG Reports Promising Sonrotoclax Results in B-Cell Malignancies at ASH 2025
  Reuters · 2025-12-08
  BeOne Medicines AG Reports Promising Sonrotoclax Results in B-Cell Malignancies at ASH 2025
- BEIGENE (06160) Grants a Total of 21,300 Restricted Share Units
  Stock News · 2025-12-04
  BEIGENE (06160) Grants a Total of 21,300 Restricted Share Units
- FDA Grants Priority Review to BeOne Medicines' Sonrotoclax for Relapsed or Refractory Mantle Cell Lymphoma
  Reuters · 2025-11-26
  FDA Grants Priority Review to BeOne Medicines' Sonrotoclax for Relapsed or Refractory Mantle Cell Lymphoma
- U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
  THOMSON REUTERS · 2025-11-26
  U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
- Beone Medicines : Truist Securities Initiates Coverage With Buy Rating; Target Price $400
  THOMSON REUTERS · 2025-11-24
  Beone Medicines : Truist Securities Initiates Coverage With Buy Rating; Target Price $400
- BeOne Medicines Unveils Promising Clinical Data on Novel BCL2 and BTK Therapies at ASH 2025
  Reuters · 2025-11-20
  BeOne Medicines Unveils Promising Clinical Data on Novel BCL2 and BTK Therapies at ASH 2025
- BeOne Medicines Q3 Net Profit At 688.8 Million Yuan
  Reuters · 2025-11-20
  BeOne Medicines Q3 Net Profit At 688.8 Million Yuan
- BRIEF-BeOne Medicines said Facilities Agreement provides U.S. Dollar-denominated, B1 revolving loan facility of $140 million
  Reuters · 2025-11-19
  BRIEF-BeOne Medicines said Facilities Agreement provides U.S. Dollar-denominated, B1 revolving loan facility of $140 million
- Beone Medicines Ltd - Accordion Feature Allows B Loan Facilities Increase to $700 Mln - SEC Filing
  THOMSON REUTERS · 2025-11-19
  Beone Medicines Ltd - Accordion Feature Allows B Loan Facilities Increase to $700 Mln - SEC Filing
- Beone Medicines Ltd - Facilities Agreement Provides U.S. Dollar-Denominated, B1 Revolving Loan Facility of $140 Mln
  THOMSON REUTERS · 2025-11-19
  Beone Medicines Ltd - Facilities Agreement Provides U.S. Dollar-Denominated, B1 Revolving Loan Facility of $140 Mln
- BeOne Medicines Secures $440 Million Dual-Currency Loan Facilities Led by HSBC
  Reuters · 2025-11-19
  BeOne Medicines Secures $440 Million Dual-Currency Loan Facilities Led by HSBC
- BEIGENE Opens Over 3% Higher in Early Trading; CSCI Maintains "Buy" Rating
  Deep News · 2025-11-18
  BEIGENE Opens Over 3% Higher in Early Trading; CSCI Maintains "Buy" Rating
Company Profile
Company Name
百济神州有限公司
Industry
医药制造业
Listing Date
2021-12-15
Registered Capital
15万元
Introduction
百济神州有限公司的主营业务是研究、开发、生产以及商业化创新型药物。公司的主要产品是百悦泽、百泽安、百汇泽、安加维、倍利妥、凯洛斯、萨温珂、凯泽百、普贝希（安维汀生物类似药）、百拓维（注射用戈舍瑞林微球）、泰菲乐（达拉非尼）、迈吉宁（曲美替尼）、维全特（帕唑帕尼）、飞尼妥（依维莫司）、赞可达（塞瑞替尼）。截至本报告期末，公司及其控股子公司拥有的发明专利包括美国发明专利64个、中国发明专利67个、日本发明专利30个、欧洲发明专利15个及其他国家或地区的发明专利135个。

1D
5D
Day
Week
Month

Loading ...

High

272.70

Open

271.00

T/O Rate

1.15%

Low

267.71

272.00

Amplitude

1.83%

To The Moon

Beone Medicines Ltd.(688235)

Company Profile

Most Discussed